Diamond Wipes’ FDA Headaches Suggest Cosmetic Recall Hangover
This article was originally published in The Rose Sheet
Executive Summary
Following an FDA warning letter in 2016 for an unapproved sunscreen drug product, Diamond Wipes now must answer agency concerns regarding “poor-quality water” used in its manufacturing operations. Both warnings stemmed from inspections in the wake of a 2014 product recall for mold contamination.
You may also be interested in...
Manufacturing Compliance Updates In Brief: A Reduced Focus On Data Integrity
US FDA has issued at least 10 GMP warning letters in February and March to drug and API manufacturers in China, India, France, South Korea, Hong Kong, the Dominican Republic and the US. Common problems seen are failure to validate manufacturing processes, inadequate testing to conform that products meet specifications, and inadequate safeguards to prevent microbiological contamination, yet in a recent turn, only a few manufacturers had data integrity problems. FDA posts Form 483 reports issued to four manufacturers in India for GMP violations and adds six facilities to its drug GMP import alert.
ICMAD Responds To Senate Proposal: Cosmetics Should Not Be Regulated Like Foods
Small business advocate says the Senate Health Committee’s discussion draft – the Modernization of Cosmetics Regulation Act – would impose burdens on industry on par with requirements for foods. But while food products continue to pose significant risks, “no such record exists for the cosmetics industry,” the trade group asserts.
FDA Wiping Market Of Verboten Sunscreen Formats Following 2016 Warnings
Consumer access to SPF-infused wipes is shrinking following FDA warning letters last year to companies that have since discontinued cited products, which the agency says are unapproved drugs ineligible for OTC sunscreen drug review. It remains to be seen how the maker of KLENSKIN Shower-On sunscreen products will respond, with its entire business model hanging in the balance.